Home /
Sanofi shares drop after abandoning atopic dermatitis treatment Sanofi announces the discontinuation of amlitelimab for atopic dermatitis.
Published 7sem · 1 source Important · updated 1sem
The fact This decision triggers a significant drop in its stock price on Friday.
The pharmaceutical group is reassessing its therapeutic priorities.
🔗 Click the link to read an article on the topic:
Why it matters L'abandon d'un traitement prometteur impacte la confiance des investisseurs et souligne les défis de la recherche pharmaceutique, où les échecs cliniques peuvent peser lourdement sur la valorisation des entreprises.
What if you saw the whole news differently? Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page. → Paris · © OpenStreetMap, OpenMapTiles, OpenFreeMap World map → Auto-synthesis from 1 media source · identified on July 24, 2026